Trials / Completed
CompletedNCT02031861
Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension
Random, Open Label, Active Comparator-controlled Parallel Study to Evaluate the Efficacy of Nifedipine Controlled-released Tablets (Xin Ran) in Patients With Mild to Moderate Essential Hypertension
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Shanghai Shyndec Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare nifedipine controlled-release (CR) tablets (Xin Ran) with nifedipine controlled-release tablets (Adalat）in the treatment of mild to moderate essential hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nifedipine CR tablets (Xin Ran) | |
| DRUG | nifedipine CR tablets (Adalat) |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2014-07-01
- Completion
- 2014-07-01
- First posted
- 2014-01-09
- Last updated
- 2015-02-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02031861. Inclusion in this directory is not an endorsement.